DE LAURENTIIS, MICHELINO
DE LAURENTIIS, MICHELINO
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA
C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases.
1996 Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part
2007 G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino
Targeted Therapy of Breast Cancer
2009 DE LAURENTIIS, Michelino; Zielinski, C.
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination.
1995 P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco
EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER.
2002 DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F.
Survival Analysis by means of a novel Neural Network Model
2003 Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino
Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer.
1995 Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer.
2014 Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G.
A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies.
1996 Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P.
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
2011 Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm
Manuale di Oncologia Clinica
1996 Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo
Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
2005 Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease.
2003 DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.
2005 DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P.
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up.
1999 DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R.
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
2006 Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R.
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A.
2000 Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo
IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE.
2003 DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| C-erbB2 overexpression decreases the benefit of adiuvant tamoxifen in early breast cancer without axillary lymph node metastases. | 1.1 Articolo in rivista | 1996 | Carlomagno, Chiara; Perrone, F.; Gallo, C.; DE LAURENTIIS, Michelino; Lauria, R.; Morabito, A.; Pettinato, G.; Bianco, A. R.; DE PLACIDO, Sabino | |
| Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part | 1.5 Abstract in rivista | 2007 | G., Tortora; Carlomagno, Chiara; Bianco, Roberto; Daniele, G; Pepe, S; Leopardo, D; Marciano, Roberta; DE LAURENTIIS, Michelino; F., Ciardiello; DE PLACIDO, Sabino | |
| Targeted Therapy of Breast Cancer | 8.01 Chairman di Sessioni di Convegni Internazionali | 2009 | DE LAURENTIIS, Michelino; Zielinski, C. | |
| Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's Lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin vincristine and prednisone (CHOP) combination. | 1.1 Articolo in rivista | 1995 | P., Tagliaferri; Matano, Elide; A., Rea; M., Famiani; F., Ciardiello; G., Tortora; V., Montesarchio; A., Morabito; M., Caraglia; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Palmieri, Giovannella; A. R., Bianco | |
| EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) CORRELATES WITH DISEASE RELAPSE AND PROGRESSION TO ANDROGEN-INDEPEDENCE IN HUMAN PROSTATE CANCER. | 1.1 Articolo in rivista | 2002 | DI LORENZO, G; Tortora, G; D'Armiento, FRANCESCO PAOLO; DE ROSA, G; Staibano, Stefania; Autorino, R; D'Armiento, Maria; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Catalano, G; Bianco, Ar; Ciardiello, F. | |
| Survival Analysis by means of a novel Neural Network Model | 1.1 Articolo in rivista | 2003 | Eleuteri, A; Tagliaferri, R; DE PLACIDO, Sabino; DE LAURENTIIS, Michelino | |
| Prognostic significance of necrosis, elestosis, fibrosis and inflammatory cell reaction in operable breast cancer. | 1.1 Articolo in rivista | 1995 | Carlomagno, Chiara; Perrone, F.; Lauria, R.; DE LAURENTIIS, Michelino; Gallo, C.; Morabito, A.; Pettinato, Guido; Panico, L.; Bellelli, T.; Apicella, A.; Putrella, G.; Bianco, ANGELO RAFFAELE; DE PLACIDO, Sabino | |
| High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. | 1.1 Articolo in rivista | 2014 | Criscitiello, C; Disalvatore, D; DE LAURENTIIS, Michelino; Gelao, L; Fumagalli, L; Locatelli, M; Bagnardi, V; Rotmensz, N; Esposito, A; Minchella, I; DE PLACIDO, Sabino; Santangelo, Michele; Viale, G; Goldhirsch, A; Curigliano, G. | |
| A-Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies. | 1.1 Articolo in rivista | 1996 | Caraglia, M.; Leardi, A.; Ricciardi, B.; DE LAURENTIIS, Michelino; Lentini, M. L.; Graziano, ; Matano, Elide; DE PLACIDO, Sabino; Bianco, ANGELO RAFFAELE; Tagliaferri, P. | |
| Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, Chiara; Ciardiello, F; DE LAURENTIIS, Michelino; Pepe, Stefano; Ruggiero, A; Tortora, Giampaolo; Panico, L; D’ ANTONIO, A; Pettinato, Guido; Petrella, Giuseppe; Bianco, Ar | |
| Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. | 1.1 Articolo in rivista | 2011 | Giordano, A; Giuliano, Mario; DE LAURENTIIS, Michelino; Eleuteri, A; Iorio, F; Tagliaferri, R; Hortobagyi, Gn; Pusztai, L; DE PLACIDO, Sabino; Hess, K; Cristofanilli, M; Reuben, Jm | |
| Manuale di Oncologia Clinica | 2.1 Contributo in volume (Capitolo o Saggio) | 1996 | Bianco, ANGELO RAFFAELE; E., Biondi; Carlomagno, Chiara; Ciardiello, Fortunato; Contegiacomo, Alma; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Lauria, Rossella; Marinelli, Alfredo; Matano, Elide; A., Morabito; Palmieri, Giovannella; Pepe, Stefano; F., Perrone; P., Tagliaferri; Tortora, Giampaolo | |
| Effect of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials | 1.1 Articolo in rivista | 2005 | Abe, O; Abe, R; Carlomagno, Chiara; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino | |
| Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. | 1.1 Articolo in rivista | 2003 | DI LORENZO, Giuseppe; Autorino, Riccardo; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, Rossella; Giordano, A; De Sio, M; D'Armiento, Massimino; Bianco, Ar; DE PLACIDO, Sabino | |
| Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. | 1.1 Articolo in rivista | 2003 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; Carlomagno, C; Gallo, C; Perrone, F; Pepe, S; Ruggiero, A; Marinelli, Alfredo; Pagliarulo, C; Panico, L; Pettinato, ; Petrella, G; Bianco, Ar | |
| A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. | 1.1 Articolo in rivista | 2005 | DE PLACIDO, Sabino; DE LAURENTIIS, Michelino; DE LENA, M; Lorusso, V; Paradiso, A; D'Aprile, M; Pistillucci, G; Farris, A; Sarobba, Mg; Palazzo, S; Manzione, L; Adamo, V; Palmeri, S; Ferrau, F; Lauria, Rossella; Pagliarulo, C; Petrella, Giuseppe; Limite, Gennaro; Costanzo, Raffaele; Bianco, Ar; GOCSI COOPERATIVE, G. R. O. U. P. | |
| Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. | 1.1 Articolo in rivista | 1999 | DE PLACIDO, Sabino; Carlomagno, C.; Ciardiello, F.; DE LAURENTIIS, Michelino; Pepe, S.; Ruggiero, A.; Tortora, G.; Panico, L.; D'Antonio, A.; Pettinato, G.; Petrella, G.; Bianco, A. R. | |
| Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. | 1.1 Articolo in rivista | 2006 | Ciardiello, F; Troiani, T; Caputo, F; DE LAURENTIIS, Michelino; Tortora, G; Palmieri, Giovannella; De Vita, F; Diadema, Mr; Orditura, M; Colantuoni, G; Gridelli, C; Catalano, G; DE PLACIDO, Sabino; Bianco, A. R. | |
| Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. | 1.1 Articolo in rivista | 2000 | Ciardiello, F; Caputo, R; Pomatico, G; DE LAURENTIIS, Michelino; DE PLACIDO, Sabino; Bianco, Ar; Tortora, Giampaolo | |
| IS THERE A STANDARD CHEMOTHERAPEUTIC REGIMEN FOR HORMONE-REFRACTORY PROSTATE CANCER? PRESENT AND FUTURE APPROACHES IN THE MANAGEMENT OF THE DISEASE. | 2.1 Contributo in volume (Capitolo o Saggio) | 2003 | DI LORENZO, G; Autorino, R; DE LAURENTIIS, Michelino; Bianco, Roberto; Lauria, R; Giordano, A; DE SIO, M; Darmiento, M; Bianco, Ar; DE PLACIDO, Sabino |